Literature DB >> 29122819

Treatment of conjunctival melanoma in a Dutch referral centre.

Niels J Brouwer1, Marina Marinkovic1, Sjoerd G van Duinen2, Jaco C Bleeker1, Martine J Jager1, Gregorius P M Luyten1.   

Abstract

AIMS: To evaluate the treatment of conjunctival melanoma at a large Dutch referral centre and to make recommendations for clinical management.
METHODS: A retrospective review was performed of clinical and histological data of 70 patients treated for a primary conjunctival melanoma between 2001 and 2014 at the Leiden University Medical Center, Leiden, the Netherlands. Detailed follow-up data were available for all patients.
RESULTS: The mean follow-up time was 70.2 months. The overall 5-year recurrence rate was 29%, the 5-year metastasis rate 12% and the 5-year melanoma-related survival 90%. Treatment with excision alone had a significantly higher 5-year recurrence rate than (the combination of) other treatments (HR 3.73,95% CI 1.19 to 11.6, P=0.02). Initial treatment in an ocular oncology centre was associated with fewer recurrences compared with initial treatment by a local ophthalmologist of a referring centre (HR 0.32,95% CI 0.11 to 0.94, P=0.04), despite similar tumour baseline characteristics.
CONCLUSION: Conjunctival melanoma is a rare disease with a high recurrence rate. A treatment strategy with local excision and adjuvant therapy gave a good clinical outcome, excision alone as a treatment should be considered obsolete. Initial treatment in a large referral centre improves clinical outcome, and patients should be referred to a specialised centre as soon as possible. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  conjunctiva; neoplasia; treatment

Mesh:

Year:  2017        PMID: 29122819     DOI: 10.1136/bjophthalmol-2017-311082

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Incidence and Survival of Patients With Conjunctival Melanoma in Europe.

Authors:  Gianni Virgili; Mariacristina Parravano; Gemma Gatta; Riccardo Capocaccia; Cinzia Mazzini; Sandra Mallone; Laura Botta
Journal:  JAMA Ophthalmol       Date:  2020-06-01       Impact factor: 7.389

2.  Two Late Recurrences of Conjunctival Melanoma.

Authors:  Niels J Brouwer; Stijn W Genders; Marina Marinkovic; Sjoerd G van Duinen; Martine J Jager; Gré P M Luyten
Journal:  Ocul Oncol Pathol       Date:  2018-12-12

3.  Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Authors:  Bennett Yau-Bun Hong; Joshua R Ford; Isabella C Glitza; Carlos A Torres Cabala; Michael Tetzlaff; Victor G Prieto; Richard Parker; Claire Daniel; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Jan-Feb 01       Impact factor: 2.011

4.  Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.

Authors:  Keting Bao; Yongyun Li; Jinlian Wei; Ruoxi Li; Jie Yang; Jiahao Shi; Baoli Li; Jin Zhu; Fei Mao; Renbing Jia; Jian Li
Journal:  Cell Death Dis       Date:  2021-04-07       Impact factor: 8.469

Review 5.  Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.

Authors:  Natasha M van Poppelen; Daniël P de Bruyn; Tolga Bicer; Rob Verdijk; Nicole Naus; Hanneke Mensink; Dion Paridaens; Annelies de Klein; Erwin Brosens; Emine Kiliҫ
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

6.  Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study.

Authors:  Puneet Jain; Paul T Finger; Maria Fili; Bertil Damato; Sarah E Coupland; Heinrich Heimann; Nihal Kenawy; Niels J Brouwer; Marina Marinkovic; Sjoerd G Van Duinen; Jean Pierre Caujolle; Celia Maschi; Stefan Seregard; David Pelayes; Martin Folgar; Yacoub A Yousef; Hatem Krema; Brenda Gallie; Alberto Calle-Vasquez
Journal:  Br J Ophthalmol       Date:  2020-09-05       Impact factor: 4.638

7.  Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature.

Authors:  Barbara Peric; Spela Leiler; Gregor Hawlina; Boris Jancar; Marko Snoj; Andraz Perhavec
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

8.  Publication trends of research on conjunctival melanoma during 1997-2022: A 25-year bibliometric study.

Authors:  Wei Xu; Ludi Yang; Shengfang Ge; Shichong Jia; Fen Gu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

9.  TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models.

Authors:  Quanchi Chen; Vadde Ramu; Yasmin Aydar; Arwin Groenewoud; Xue-Quan Zhou; Martine J Jager; Houston Cole; Colin G Cameron; Sherri A McFarland; Sylvestre Bonnet; B Ewa Snaar-Jagalska
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639

10.  Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas.

Authors:  Juliette Thariat; Julia Salleron; Celia Maschi; Edouard Fevrier; Sandra Lassalle; Lauris Gastaud; Stephanie Baillif; Audrey Claren; Florent Baumard; Joel Herault; Jean Pierre Caujolle
Journal:  Radiat Oncol       Date:  2019-12-27       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.